Literature DB >> 30403550

Clinical Application and Potential of Fecal Microbiota Transplantation.

R E Ooijevaar1, E M Terveer2, H W Verspaget3, E J Kuijper2, J J Keller3,4.   

Abstract

Fecal microbiota transplantation (FMT) is a well-established treatment for recurrent Clostridioides difficile infection. FMT has become a more readily available and useful new treatment option as a result of stool banks. The current state of knowledge indicates that dysbiosis of the gut microbiota is implicated in several disorders in addition to C. difficile infection. Randomized controlled studies have shown FMT to be somewhat effective in treating ulcerative colitis, irritable bowel syndrome, and hepatic encephalopathy. In addition, FMT has been beneficial in treating several other conditions, such as the eradication of multidrug-resistant organisms and graft-versus-host disease. We expect that FMT will soon be implemented as a treatment strategy for several new indications, although further studies are needed.

Entities:  

Keywords:  infection; CDI; FMT; IBD; IBS; fecal microbiota transplantation; hepatic encephalopathy; inflammatory bowel disease; irritable bowel syndrome

Mesh:

Year:  2018        PMID: 30403550     DOI: 10.1146/annurev-med-111717-122956

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  53 in total

1.  Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug.

Authors:  Josbert J Keller; Maria Jgt Vehreschild; Christian L Hvas; Simon Md Jørgensen; Jouzas Kupciskas; Alexander Link; Chris Jj Mulder; Simon D Goldenberg; Ramesh Arasaradnam; Harry Sokol; Antonio Gasbarrini; Christoph Hoegenauer; Elizabeth M Terveer; Ed J Kuijper; Perttu Arkkila
Journal:  United European Gastroenterol J       Date:  2019-11-14       Impact factor: 4.623

Review 2.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

Review 3.  Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome.

Authors:  Ziying Zhang; Haosheng Tang; Peng Chen; Hui Xie; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2019-10-12

Review 4.  Changes of intestinal microbiota and microbiota-based treatments in IBD.

Authors:  Qianyu Li; Siyu Zhou; Yanna Wang; Jing Cong
Journal:  Arch Microbiol       Date:  2022-07-01       Impact factor: 2.552

5.  Efficacy of faecal microbiota transplantation on ulcerative colitis and its effect on gastrointestinal motility and immune function.

Authors:  Dengshun Lei; Hong Xu; Renqun Peng; Mei Yang; Xinghui Li; Wei Zuo; Juhua Gou; Shuangjiang Yu; Min Huang; Hao Liu
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 6.  Evolutionary Insights Into Microbiota Transplantation in Inflammatory Bowel Disease.

Authors:  Xiaoli Wang; Jingwen Zhao; Yuanhang Feng; Zelin Feng; Yulin Ye; Limin Liu; Guangbo Kang; Xiaocang Cao
Journal:  Front Cell Infect Microbiol       Date:  2022-06-22       Impact factor: 6.073

7.  Microbiome as an Immunological Modifier.

Authors:  Manoj Kumar; Parul Singh; Selvasankar Murugesan; Marie Vetizou; John McCulloch; Jonathan H Badger; Giorgio Trinchieri; Souhaila Al Khodor
Journal:  Methods Mol Biol       Date:  2020

Review 8.  Bone marrow chimeras-a vital tool in basic and translational research.

Authors:  Filipa M Ferreira; Pushpalatha Palle; Johannes Vom Berg; Prajwal Prajwal; Jon D Laman; Thorsten Buch
Journal:  J Mol Med (Berl)       Date:  2019-04-26       Impact factor: 4.599

Review 9.  Gut Microbial Changes and their Contribution to Post-Burn Pathology.

Authors:  Marisa E Luck; Caroline J Herrnreiter; Mashkoor A Choudhry
Journal:  Shock       Date:  2021-09-01       Impact factor: 3.533

10.  Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial.

Authors:  Anna-Maria Hoffmann-Vold; Håvard H Fretheim; Vikas K Sarna; Imon Barua; Maylen N Carstens; Oliver Distler; Dinesh Khanna; Elizabeth R Volkmann; Øyvind Midtvedt; Henriette Didriksen; Alvilde Dhainaut; Anne-Kristine Halse; Gunnstein Bakland; Maiju Pesonen; Inge Olsen; Øyvind Molberg
Journal:  BMJ Open       Date:  2021-06-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.